小蘖碱
Antiproliferative activity of berberine in vitro and in vivoday 0, 5, 9, 12 and 16. The weight of carboxymethylcellu-lose-injected animals did not changed remarkably during the experiment. The weights of the animals treated with berberine at concentrations of 1 and 5 mg/kg did not dif-fer from the weight of the control group. On the other hand, the weight of the animals treated with berberine at concentration of 10 mg/kg was slightly decreased by 3.3 % on day 5 compared to the control, but in the next time interval, on day 9, the decrease was 5.8 % in comparison with the control on day 9. On day 12, the weight decrease between animals treated with 10 mg/kg and control was 6.6 %. In the next time interval, on day 16, the weight was 463
number was found. The cytotoxic e ect of berberine at the next tested concentrations (0.1, 0.01 and 0.001 µg/ml) was directly proportional to the concentration and the time of in uence. Similar type of combined cytotoxic e ect by monitoring the e ects of berberine on proliferation of the HeLa and L1210 cells3 was observed. Because of the signi cant in vitro antiproliferative e ects of berberine achieved, the antitumor activity in vivo was investigated. First of all the toxicity of the drug on C57BL/6 mice in the range of concentrations from 10 mg/kg to 50 mg/kg was studied and the LD50, less than 50 mg/kg, (for intra-peritoneal injection) value was determined. Then the can-inhibited by 6.7 %. The statistically signi cant di erences were observed when comparing the highest tested concen-tration, 10 mg/kg, with the control on day 9, 12 and 16.The injected animals were also examined twice per week for tumor growth. Five days following cell inocula-tion, the appearance of small solid tumors was observed. Concentrations 1, 5 and 10 mg/kg injection did not re-duce tumor volume on day 5, 9 and 12 in comparison with the control (Fig. 3). On day 16, the dose of 1 mg/kg reduced tumor volume by 1.1 %, 5 mg/kg by 11.3 % and 10 mg/kg by 26.2 % compared to carboxymethylcellulose-injected animals. The statistically signi cant di erence was observed when comparing the highest tested dose, 10 mg/kg, with the control on day 9 (P = 0.046).
By day 16, the group treated with berberine at dose of 1 mg/kg grew slightly bigger tumors than carboxymethyl-cellulose-treated animals (Fig. 4). However, there was no statistically signi cant di erence between the two groups (P = 0.14). Tumor mass in animals treated with 5 mg/kg was reduced by 30.8 % compared to the control group with statistically signi cant di erence (P = 0.014). Injection of berberine at concentration of 10 mg/kg re-sulted in similar tumor mass reduction as that induced by 5 mg/kg compared to the control group, reduction was 36.6 %. However, there was no statistically signi cant dif-ference between the two groups (P = 0.08).
As it follows from the growth curves of the B16 cells (Fig. 1), berberine caused di erent cytotoxic e ects de-pending on concentration and time of in uence. The high-est tested concentrations of berberine induced an acute cytotoxic e ect which was manifested by the decrease of viable B16 cell number. Berberine at concentration 1 µg/ml induced a delayed cytotoxic e ect. While after the rst 24 h of in uence the increased cell number was monitored, in the next time interval the decrease of cell
cerostatic activity in vivo was studied with the transplanted B16 line in the range of doses from 1 mg/kg to 10 mg/kg. Berberine administered intraperitoneally at doses of 1 and 5 mg/kg did not a ect the weight of the animals. The dose of 10 mg/kg sligthly reduced the weight of the animals, on day 16 the weight reduction was 6.7 % (Fig. 2). On the other hand, not even tumor volume was a ected on day 5, 9 and 12 (Fig. 3). The signi cant reduction of tumor volume was rst observed on day 16 at doses of 5 and 10 mg/kg. The tumor weight on day 16 is shown in Fig. 4. Concentration 1 mg/kg stimulated the tumor mass, but other tested concentrations, 5 and 10 mg/kg reduced the tumor weight. We can conclude that after long-term ef-fect berberine has shown anticancer activity on C57BL/6 mice, while the tumor weight and tumor volume reduction are not at the expence of the animal weight.
It is known that the e ect of the drug depends on the application dose, way of application and dose interval. The change of application way of berberine and its e ect on anticancer activity will be the object of our next stud-ies.
ACKNOWLEDGEMENT
This study was supported by the Slovak State Committee for Scienti c Research VEGA, grant numbers 1/1173/04 and Science and Technology Assistance Agency under the con-tract No. APVT-20-007304 and APVT-51-019402.REFERENCES
1. Shen YJ. Chinese Pharmacology. Shanghai Science and Tech nology
Publishing Company, 1997. p. 50–2.
2. Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino
S, Abe T, Morioka T, Hazama S, Oka M. (2000) Inhibitory e ect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett 148, 19–25.
3. Jantová S, ipák L, erňaková M, Ko álová D. (2003) E ect of
berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol 55, 1143–9.
黑色素瘤介绍 主要内容 1 2 3 4 黑色素瘤形成与发病机制 黑色素瘤临床表现 治疗与预后 黑色素瘤(melanoma) 黑色素瘤是一种能产生黑色素的高度恶性肿瘤,又称...
黑人少见。编辑本段分类 构成所有的恶性黑色素瘤只有一种恶性细胞类型,即被称作黑色素细胞的恶性色素产生细胞,但它们通过其形态,如梭形、圆柱形,而存在一些很少的...
19 ? 5 中 国黑 色素瘤诊治指南(0 )21 1版 CC黑 色素 瘤专 家委 员会 SO 【 关键词 】 恶性黑色素瘤 ;中国; 诊断; 治疗 ; 指南 中图分类号:795...
部分恶黑呈现皮肤色,又叫作 无色素的恶性黑素瘤。 欧美高加索白种人最常见的是浅表扩散型恶性黑素瘤, 主要分布于躯干和四肢, 从病理上看 主要是以水平侵袭为主...
http://www.qiuyi.cn/ 黑色素瘤的预防方法有哪些黑色素瘤 60%是由黑痣恶变的,因此如果发现身体各个部位的小黑痣出现增大、颜色 加深, 边缘不规则,甚至发痒、破...
恶性黑色素瘤_临床医学_医药卫生_专业资料。恶性黑色素瘤 (malignant melanoma,MM) 目录一、 二、 三、 四、 五、 六、 七、 八、 九、 概述 流行病学与...
赴美就医-黑色素瘤患者的福音_临床医学_医药卫生_专业资料。我现在已经开始了我的新生活。毕竟,我经历过了癌症 - 我自己的癌还有简的- 我把自己训练成为一名...
黑色素瘤_临床医学_医药卫生_专业资料。恶性黑色素瘤是一种产生黑色素的高度恶性肿瘤,仅少数为无色素恶性黑色素瘤。发病率为全部恶性肿瘤的1%-3%,近年有上升...
NRAS突变的黑色素瘤分子机制研究进展_医药卫生_专业资料。NRAS 突变的黑色素瘤分子机制研究进展 【摘要】NRAS 突变的黑色素瘤中有一些经典的信号通路,与肿瘤的...
热门文档